20.09.2016

Vela Genomics Launches Early Access to TheraKey™

SINGAPORE – 20 SEPTEMBER, 2016 – Vela Genomics, a subsidiary of Vela Diagnostics, announced today the availability of TheraKey™, a clinical interpretation reporting service, for early access customers.

TheraKey™ provides clinicians with a complete Patient-to-Treatments matching solution to accelerate the adoption of Next-Generation Sequencing (NGS) in routine clinical diagnostics.

“Empowering clinicians with information on available treatment options and up-to-date relevant clinical trials will greatly help them to make timely decisions on the best treatment for patients,” said Charlie Lee, PhD, Head of Research and Development of Vela Genomics. “This comprehensive data-driven approach significantly reduces time, manpower, costs and the risks of making an uninformed treatment decision. This is the true realization of Personalized Medicine.”

One of the biggest challenges clinicians face when using NGS for routine clinical diagnosis is the interpretation of genomics data and subsequent application. Generating an actionable clinical report from genomic data, that could be potentially huge, is typically a time-consuming and inconsistent manual process that entails cross referencing information across multiple data sources. With TheraKey™, clinicians need to submit only the Variant Calling File (VCF) and disease diagnosis of their patients to receive corresponding actionable clinical reports within 1 to 3 working days.

TheraKey™ is powered by a proprietary Natural Language Processing (NLP) engine and analytics pipeline that extracts, filters and agglomerate key entities such as genes, mutations, diseases, treatments and drug response from over 40 public and commercial databases on a regular basis. TheraKey™ is designed to generate an easy to read clinical report that has a clear and concise summary of relevant therapies and clinical trials.

Besides drugs approved by the Food and Drugs Administration (FDA) for the specific disease and gene or variant, the report also indicates other drugs approved by regulatory bodies, and investigational drugs that could be effective for the patient, providing clinicians with the broadest treatment options available. Up-to-date clinical trials that have the most relevance to the genomic biomarkers, disease diagnosis, eligibility and location proximity of the patient are included in the report as well.

Finally, all reports are verified by highly qualified curators adhering to the National Comprehensive Cancer Network (NCCN) Guidelines®, highlighting contraindicated therapies if any, before they are made available to clinicians. This guarentees a timely, consistent and accurate clinical report that clinicians can use to provide tailored treatments to their patients.

Vela Genomics will initially focus on cancer, with the intention to expand to infectious diseases and other genetic diseases. A database comprising of genomic data from samples donated by patients from collaborators, coupled with associated clinical and drug response data will be developed to provide new insights into the biology of diseases and aid in the identification of novel drug targets. More details will be available in the coming months.

Early access to TheraKeyTM is currently available at www.velagenomics.com.

For enquires, please email This email address is being protected from spambots. You need JavaScript enabled to view it..

Get The Latest Updates on Vela Genomics